FDA’s Center for Drug Evaluation and Research decides whether to grant or deny “breakthrough therapy” designation requests based on the totality of evidence available for a product, not any one efficacy data point, agency officials said April 24.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?